You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Mallinckrodt
McKesson
Express Scripts
Medtronic

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

Braintree Labs Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Braintree Labs
International Patents:18
US Patents:1
Tradenames:3
Ingredients:3
NDAs:3

Drugs and US Patents for Braintree Labs

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Braintree Labs PIZENSY lactitol FOR SOLUTION;ORAL 211281-001 Feb 12, 2020 RX Yes Yes   Start Trial   Start Trial
Braintree Labs SUPREP BOWEL PREP KIT magnesium sulfate; potassium sulfate; sodium sulfate SOLUTION;ORAL 022372-001 Aug 5, 2010 AA RX Yes Yes 6,946,149   Start Trial Y   Start Trial
Braintree Labs SUCLEAR magnesium sulfate; polyethylene glycol 3350; potassium chloride; potassium sulfate; sodium bicarbonate; sodium chloride; sodium sulfate SOLUTION;ORAL 203595-001 Jan 18, 2013 DISCN Yes No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for BRAINTREE LABS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Solution 17.5 g/3.13 g/1.6 g per bottle ➤ Subscribe 2010-11-08

Supplementary Protection Certificates for Braintree Labs Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0984957 CR 2012 00035 Denmark   Start Trial PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
0984957 122012000017 Germany   Start Trial PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812
1499331 SPC/GB13/034 United Kingdom   Start Trial PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
1499331 C20130010 00080 Estonia   Start Trial PRODUCT NAME: NAATRIUMSULFAAT, MAGNEESIUMSULFAATHEPTAHUEDRAAT JA;REG NO/DATE: RR-4/5 04.03.2013
1499331 132013902184107 Italy   Start Trial PRODUCT NAME: (SODIO SOLFATO + MAGNESIO SOLFATO + POTASSIO SOLFATO(IZINOVA); AUTHORISATION NUMBER(S) AND DATE(S): BE434323, 20130220;041807013/M, 20130610
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Medtronic
Johnson and Johnson
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.